Given that we observed that B-CLL cells express high levels of GSK-3, and our data strongly suggest that it does not restrain their NF-κB activity, we sought to explore the combinatorial effect of both GSK-3β and NEDDylation inhibition in these cells. Here, NFKB1 is linked to B-cell chronic lymphocytic leukemia.